First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery. The study will follow adults receiving this treatment in routine medical care in Japan to understand how safe it is, how well it works, and how it is used in standard clinical practice.

NCT Number	NCT07679061
Lead Sponsor	Bristol-Myers Squibb Collaborators: Ono Pharmaceutical Co., Ltd.
Conditions	Unresectable Hepatocellular Carcinoma
Enrollment	200 participants
Start Date	2026-03-05
Primary Completion	2028-02-29 (estimated)
Study Completion	2028-02-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-01